Dale Schaar
Medical Oncology · New Brunswick, NJNPI 1568547768
Payments from drug & device makers
What this record shows
This record is dominated by charitable contributions: $1,000 of the $1,033 with a category attached, or 96.8%. E.r. Squibb & Sons, L.L.C. accounts for 96.8% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for medical oncology clinicians in NJ, where the typical reported total is $1,937.
Across 3 payments — averaging $344.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Gilead$20
- Novartis$13
Across 39 payments — averaging $39,235 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.3M
- Rigel Pharmaceuticals, Inc.$64K
- PTC Therapeutics, Inc.$57K
- AbbVie$49K
- Incyte Corporation$28K
- Syndax Pharmaceuticals, Inc.$23K
- plus $14K from 1 others
What the payments were for
- Food & beverage$333%
- Charitable contribution$1,00097%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $1,000 |
| Gilead | 1 | $20 |
| Novartis | 1 | $13 |
How this compares
$1,033 in reported general payments places this provider in the 40th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 20 | $405,676 |
| SprycelDasatinib | 17 | $237,901 |
| GleevecImatinib Mesylate | 18 | $141,986 |
| VenclextaVenetoclax | 13 | $67,515 |
| Imatinib Mesylate | 12 | $4,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Gleevec | $13 | $547,66238 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $1,000 | $237,90117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in New Brunswick
- Kristen SpencerNew Brunswick$50K
- Sarah WeissNew Brunswick$30K
- Missak HaigentzNew Brunswick$30K
- Patrick BolandNew Brunswick$29K
- Shridar GanesanNew Brunswick$27K
- Roman GroisbergNew Brunswick$22K
- Deborah ToppmeyerNew Brunswick$21K
- Morana VojnicNew Brunswick$16K
- Sanjay GoelNew Brunswick$13K
- Tina MayerNew Brunswick$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.